---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-154636"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2024-06-05T23:59:59+00:00"
generated_at: "2026-06-01T06:18:14.109087+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vir reports high virologic response in Phase 2 SOLSTICE hepatitis delta trial

## Summary
- De novo tobevibart+elebsiran combination: 64% (7/11) combined endpoint at week 24.
- Tobevibart monotherapy: 55% (6/11) combined endpoint at week 24.
- No serious adverse events, no ALT flares; majority of AEs Grade 1-2 and transient.
- Company to report additional 24-week data for all ~60 participants in Q4 2024.
- Data to be presented at EASL Congress on June 8, 2024.

## SEC filing metadata
- accession: 0001193125-24-154636
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2024-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000119312524154636/0001193125-24-154636-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000119312524154636/d819044d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-154636
- JSON: https://secwatch.observer/filing/0001193125-24-154636.json
- Plain text: https://secwatch.observer/filing/0001193125-24-154636.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.